Table 1.
Characteristics of donors, recipients, and transplant according to percent GS in transplanted allograft.
| Glomerulosclerosis | |||||
|---|---|---|---|---|---|
| 0–10% | 11–20% | >20% | No-Biopsy | p-Value | |
| N | 7796 | 1230 | 500 | 786 | |
| Donor | |||||
| Age (years) | 60.7 ± 7.1 | 60.5 ± 6.9 | 60.6 ± 6.7 | 58.5 ± 7.4 | <0.001 |
| Male (%) | 46.7 | 41.1 | 46.4 | 36.6 | <0.001 |
| Black (%) | 28.8 | 29.5 | 25.2 | 30.0 | 0.26 |
| Diabetes (%) | 26.5 | 34.2 | 30.6 | 20.2 | <0.001 |
| Hypertension (%) | 79.0 | 81.8 | 80.8 | 73.8 | <0.001 |
| BMI (kg/m2) | 28.8 ± 6.9 | 29.2 ± 7.5 | 29.2 ± 7.5 | 27.3 ± 6.5 | <0.001 |
| Creatinine (mg/dL) before kidney procurement | 1.2 ± 1.0 | 1.2 ± 0.6 | 1.2 ± 0.5 | 1.2 ± 1.0 | 0.04 |
| Donor after cardiac death (%) | 10.0 | 7.1 | 6.8 | 4.6 | <0.001 |
| HCV antibody positive (%) | 5.8 | 2.4 | 2.8 | 12.9 | <0.001 |
| Cause of death (%) | |||||
| Cerebrovascular accident | 78.1 | 79.4 | 83.0 | 82.8 | 0.002 |
| Machine perfusion (%) | 49.9 | 51.2 | 47.8 | 19.5 | <0.001 |
| Expanded criteria donor (%) | 85.4 | 87.7 | 86.4 | 75.5 | <0.001 |
| Recipient | |||||
| Age (years) | 61.5 ± 9.8 | 62.4 ± 9.6 | 61.6 ± 9.8 | 59.9 ± 10.6 | 0.001 |
| Male (%) | 64.0 | 63.1 | 63.2 | 63.9 | 0.92 |
| Black (%) | 36.4 | 36.8 | 40.6 | 33.3 | 0.07 |
| BMI | 27.9 ± 5.3 | 28.4 ± 5.5 | 27.5 ± 5.0 | 27.6 ± 5.4 | 0.001 |
| Diabetes (%) | 47.2 | 46.8 | 48.8 | 47.1 | 0.90 |
| Dialysis duration (%) | |||||
| Preemptive | 9.8 | 8.9 | 9.8 | 9.0 | 0.70 |
| <1 years | 8.7 | 8.1 | 7.0 | 9.5 | 0.41 |
| 1–3 years | 29.6 | 26.7 | 30.8 | 30.7 | 0.13 |
| >3 years | 49.4 | 54.0 | 48.4 | 46.8 | 0.006 |
| PRA (%) | |||||
| <10 | 81.7 | 84.7 | 81.8 | 78.1 | 0.003 |
| 10–60 | 12.0 | 9.8 | 12.6 | 15.0 | 0.005 |
| >60 | 5.9 | 4.6 | 4.4 | 5.7 | 0.21 |
| Missing | 0.5 | 0.9 | 1.2 | 1.2 | 0.01 |
| Transplant | |||||
| HLA DR mismatch (%) | |||||
| 0 | 8.2 | 7.2 | 7.8 | 8.9 | 0.42 |
| 1 | 39.0 | 36.3 | 38.4 | 36.9 | 0.27 |
| 2 | 52.8 | 56.5 | 53.8 | 54.2 | 0.12 |
| Cold ischemic time (hours) | 19.5 ± 9.4 | 20.5 ± 9.5 | 19.8 ± 9.1 | 15.7 ± 9.2 | <0.001 |
| Transplant period | |||||
| 2005–2007 | 28.6 | 22.7 | 35.0 | 45.2 | <0.001 |
| 2008–2010 | 33.8 | 31.6 | 35.6 | 27.4 | 0.001 |
| 2011–2014 | 37.6 | 45.7 | 29.4 | 27.5 | <0.001 |
| Induction therapy (%) | |||||
| Thymoglobulin | 46.1 | 52.3 | 51.4 | 47.3 | <0.001 |
| Alemtuzumab | 14.7 | 13.5 | 16.0 | 9.5 | 0.001 |
| Basiliximab | 18.9 | 19.2 | 17.2 | 24.7 | 0.001 |
| Other induction | 7.6 | 8.1 | 5.2 | 7.1 | 0.19 |
| No induction | 16.3 | 11.0 | 13.4 | 15.0 | <0.001 |
GS, glomerulosclerosis; HCV, hepatitis C virus; BMI, body mass index; PRA, panel reactive antibody; HLA, human leukocyte antigen.